ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2023
Urine and Plasma Markers of Platelet Activation and Respiratory Symptoms in COPD.
Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Isoflavone Intake is Associated With Decreased Chronic Obstructive Pulmonary Disease Morbidity.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026Article
- Mendelian Randomization Study in East Asian Populations Supports the Causal Relationship Between Blood Metabolites and COPD: Insights from Amino Acids, Phospholipids, Vitamin D, and Trace Elements.International journal of chronic obstructive pulmonary disease · 2026Article
- Standard Risk Scores Inadequately Estimate Subclinical Coronary Artery Disease in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2025Article
- Platelet activation and COPD-related clinical and imaging characteristics: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study.Respiratory medicine · 2025Article
- Perceived Stress is Associated with Health Outcomes, Platelet Activation, and Oxidative Stress in COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- High Pan-Immune Inflammation Values are Associated with Prolonged Length of Hospital Stay in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.International journal of general medicine · 2025Article
- Longitudinal anemia status and risk for adverse outcomes in former smokers with COPD.Respiratory research · 2024Article
- Airway and Systemic Prostaglandin E2 Association with COPD Symptoms and Macrophage Phenotype.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023Article
- Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences.Therapeutic advances in chronic disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Introduction: Antiplatelet therapy has been associated with fewer exacerbations and reduced respiratory symptoms in chronic obstructive pulmonary disease (COPD). Whether platelet activation is associated with respiratory symptoms in COPD is unknown. Methods: Former smokers with spirometry-confirmed COPD had urine 11-dehydro-thromboxane B2 (11dTxB2), plasma soluble CD40L (sCD40L), and soluble P-selectin (sP-selectin) repeatedly measured during a 6- to 9-month study period. Multivariate mixed-effects models adjusted for demographics, clinical characteristics, and medication use evaluated the association of each biomarker with respiratory symptoms, health status, and quality of life. Results: Among 169 participants (average age 66.5±8.2 years, 51.5% female, 47.5±31 pack years, forced expiratory volume in 1 second percent predicted 53.8±17.1), a 100% increase in 11dTxB2 was associated with worse respiratory symptoms reflected by higher scores on the COPD Assessment Test (β 0.77, 95% confidence interval [CI]: 0.11-1.4) and Ease of Cough and Sputum Clearance Questionnaire β 0.77, 95%CI: 0.38-1.2, worse health status (Clinical COPD Questionnaire β 0.13, 95%CI: 0.03-0.23) and worse quality of life (St George's Respiratory Questionnaire β 1.9, 95%CI: 0.39-3.4). No statistically significant associations were observed for sCD40L or sP-selectin. There was no consistent statistically significant effect modification of the relationship between urine 11dTxB2 and respiratory outcomes by history of cardiovascular disease, subclinical coronary artery disease, antiplatelet therapy, or COPD severity. Conclusions: In stable moderate-severe COPD, elevated urinary11dTxB2, a metabolite of the platelet activation product thromboxane A2, was associated with worse respiratory symptoms, health status, and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.